WallStSmart

Absci Corp (ABSI)vsBeOne Medicines AG (ONC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

BeOne Medicines AG generates 423122% more annual revenue ($6.61B vs $1.56M). ONC leads profitability with a 13.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 68/100 (B-).

ABSI

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: -0.85

ONC

Strong Buy

68

out of 100

Grade: B-

Growth: 10.0Profit: 7.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABSISignificantly Overvalued (-65.6%)

Margin of Safety

-65.6%

Fair Value

$1.57

Current Price

$7.51

$5.94 premium

UndervaluedFair: $1.57Overvalued
ONCUndervalued (+80.8%)

Margin of Safety

+80.8%

Fair Value

$1828.58

Current Price

$390.94

$1437.64 discount

UndervaluedFair: $1828.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABSI1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

ONC4 strengths · Avg: 9.3/10
Revenue GrowthGrowth
33.8%10/10

Revenue surging 33.8% year-over-year

EPS GrowthGrowth
212.5%10/10

Earnings expanding 212.5% YoY

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.718/10

Growing faster than its price suggests

Areas to Watch

ABSI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.74B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
51.2x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABSI

The strongest argument for ABSI centers on Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.71 suggests the stock is reasonably priced for its growth.

Bear Case : ABSI

The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 51.2x leaves little room for execution misses.

Key Dynamics to Monitor

ABSI profiles as a value stock while ONC is a growth play — different risk/reward profiles.

ABSI carries more volatility with a beta of 2.19 — expect wider price swings.

ONC is growing revenue faster at 33.8% — sustainability is the question.

ONC generates stronger free cash flow (474M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (68/100 vs 20/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Absci Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.

Visit Website →

BeOne Medicines AG

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?